Crisaborole

CAS: 906673-24-3

Ref. 3D-FC166718

Información del producto

• Nombre: Crisaborole
• Sinónimos: AN27284-[(1,3-Dihydro-1-hydroxy-2,1-benzoxaborol-5-yl)oxy]benzonitrile, 4-[(1,3-Dihydro-1-hydroxy-2,1-benzoxaborol-5-yl)oxy]benzonitrile, 4-[(1-Hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl)oxy]benzonitrile, An 2728, An2728, Benzonitrile, 4-[(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-5-yl)oxy]-, Eucrisa, Staquis

Descripción

Crisaborole is a topical antimicrobial peptide that was approved by the FDA in 2017 for the treatment of mild to moderate atopic dermatitis and eczema. It belongs to a class of drugs called small-molecule inhibitors of phosphodiesterase 4 (PDE4). PDE4 is an enzyme that hydrolyzes cyclic adenosine monophosphate (cAMP) and thereby reduces the levels of cAMP in cells. Crisaborole binds to the PDE4 enzyme and blocks its activity, leading to an increase in the level of cAMP. This increased concentration of cAMP leads to suppression of inflammation, which is a major symptom associated with skin diseases such as dermatitis and eczema.

Crisaborole has shown low toxicity in vivo studies on human volunteers. In a study involving administration of crisaborole at doses up to 300 mg/day for 14 days, adverse events were reported by 3% patients, with no serious adverse

• Marca: Biosynth

Propiedades químicas

• Peso molecular: 251.05 g/mol
• Fórmula: C₁₄H₁₀BNO₃
• Pureza: Min. 95%
• Color/Forma: Powder
• InChI: InChI=1S/H3N/h1H3
• Clave InChI: InChIKey=QGZKDVFQNNGYKY-UHFFFAOYSA-N
• SMILES: N#Cc1ccc(Oc2ccc3c(c2)COB3O)cc1